Compare Northrop Grumman Corporation (NOC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Northrop Grumman Corporation trades at $574.99 (market cap $81.78B), while State Street SPDR S&P Biotech ETF trades at $159.15. The key difference: Northrop Grumman Corporation pays a 1.63% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Northrop Grumman Corporation nearer its low. Which is the better fit depends on your goals.
| NOC | XBI | |
|---|---|---|
Market Cap | $81.78B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $768.02 | $164.28 |
52-Week Low | $496.02 | $86.92 |
Enterprise Value | $95.77B | — |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.89, up 1.1% today, with a bullish technical signal from moving averages and a record $105 billion backlog supporting fundamentals. Recent Q2 2026 earnings beat expectations, with sales growth of 5% and raised full-year guidance (Seeking Alpha, 2026-07-23). Valuation ratios like P/E of 18.3 and ROE of 26.96% reflect strong profitability, though RSI levels indicate overbought conditions.
The outlook is positive due to defense spending tailwinds and strategic contracts, but risks include margin pressure from specific programs and geopolitical volatility. Analysts maintain a buy consensus with a $598.57 price target, suggesting modest upside from current levels.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
